The pharmaceutical world is witnessing a major shift in diabetes therapy with the emergence of GLP-1 skin applications. These devices offer a possibly more comfortable alternative to subcutaneous administrations of GLP-1 medications, lessening the frequency of daily needle pokes. The approach rel